惰性B细胞淋巴瘤继发第二肿瘤研究进展
Research Progress in Secondary Tumors of Indolent B-Cell Lymphoma
摘要: 惰性B细胞淋巴瘤属于非霍奇金淋巴瘤，整体约占非霍奇金淋巴瘤的46%，且有继续增长的趋势。临床上主要表现为肿瘤细胞生长速度和疾病进展缓慢，常于化疗后有残余淋巴结，难以达到完全缓解，易出现复发的特点。随着治疗方式的改变，新的靶向药物的应用，生存率虽然有所提高，但并发第二肿瘤的报道也越来越多，尤其是慢性淋巴细胞白血病和滤泡淋巴瘤发生率较高，第二肿瘤的发生影响了患者的预后并逐渐成为其死亡的主要原因，掌握第二肿瘤的发病率及危险因素，对高危人群做好监测及随访，及早发现并予以合适的治疗方案非常重要。因此本文主要对其继发第二肿瘤的风险及其危险因素进行综述。
Abstract: Indolent B-cell lymphoma is non-Hodgkin’s lymphoma, accounting for about 46% of all non- Hodgkin’s lymphomas, and is on the rise. Clinically, the main manifestations are slow growth rate of tumor cells and slow progression of the disease, often with residual lymph nodes after chemotherapy, which is difficult to achieve complete remission and easy to relapse. With the application of targeted drugs, the survival rate has been improved, but there are more and more reports of complication of second tumor. Especially chronic lymphocytic leukemia and follicular lymphoma, the occurrence of the second tumor affects the prognosis of patients and gradually becomes the main cause of their death. It is very important to master the incidence and risk factors of the second tumor, monitor and follow up the high-risk population, and make early detection and appropriate treatment plan. Therefore, this paper mainly reviews the risk and risk factors of secondary tumors.
文章引用：周书霞. 惰性B细胞淋巴瘤继发第二肿瘤研究进展[J]. 临床医学进展, 2021, 11(9): 4079-4085. https://doi.org/10.12677/ACM.2021.119595

参考文献

[1] Al-Hamadani, M., Habermann, T.M., Cerhan, J.R., Macon, W.R., Maurer, M.J. and Go, R.S. (2015) Non-Hodgkin Lymphoma Subtype Distribution, Geodemographic Patterns, and Survival in the US: A Longitudinal Analysis of the National Cancer Data Base from 1998 to 2011. American Journal of Hematology, 90, 790-795. [Google Scholar] [CrossRef] [PubMed]
[2] Denizon, N., Baugier de Materre, A., Alani, M., Ghnaya, H., Farhi, J., Besançon, A., et al. (2018) Significant Impact of Immunosuppression on the Incidence of Secondary Malignancies Following Fludarabine, Cyclophosphamide, and Rituximab (FCR) Treatment in Patients with Indolent B-Cell Neoplasms. Leukemia & Lymphoma, 59, 2711-2714. [Google Scholar] [CrossRef] [PubMed]
[3] Rossi, C., Jégu, J., Mounier, M., Dandoit, M., Colonna, M., Daubisse-Marliac, L., et al. (2015) Risk Assessment of Second Primary Cancer According to Histological Subtype of Non-Hodgkin Lymphoma. Leukemia & Lymphoma, 56, 2876-2882. [Google Scholar] [CrossRef] [PubMed]
[4] Giri, S., Bhatt, V.R., Verma, V., Pathak, R., Gregory Bociek, R., Vose, J.M., et al. (2017) Risk of Second Primary Malignancies in Patients with Follicular Lymphoma: A United States Population-Based Study. Clinical Lymphoma, Myeloma & Leukemia, 17, 569-574. [Google Scholar] [CrossRef] [PubMed]
[5] Sorigue, M., Prusila, R.E.I., Jauhiainen, J., Mercadal, S., Postila, A., Salmi, P., et al. (2019) Incidence of Solid Cancer in Patients with Follicular Lymphoma. Acta Oncologica, 58, 1564-1569. [Google Scholar] [CrossRef] 
[6] Herr, M.M., Schonfeld, S.J., Dores, G.M., Engels, E.A., Tucker, M.A., Curtis, R.E., et al. (2019) Risk for Malignancies of Infectious Etiology among Adult Survivors of Specific Non-Hodgkin Lymphoma Subtypes. Blood Advances, 3, 1961-1969. [Google Scholar] [CrossRef] [PubMed]
[7] Chavez, J.C., Dalia, S., Sandoval-Sus, J., Kharfan-Dabaj, M.A., Al-Ali, N., Komrokji, R., et al. (2015) Second Myeloid Malignancies in a Large Cohort of Patients with Chronic Lymphocytic Leukemia: A Single Institution Experience. Clin Lymphoma Myeloma Leuk, 15, S14-S18. [Google Scholar] [CrossRef] [PubMed]
[8] Prusila, R.E.I., Sorigue, M., Jauhiainen, J., Mercadal, S., Postila, A., Salmi, P., et al. (2019) Risk of Secondary Haematological Malignancies in Patients with Follicular Lymphoma: An Analysis of 1028 Patients Treated in the Rituximab Era. British Journal of Haematology, 187, 364-371. [Google Scholar] [CrossRef] [PubMed]
[9] Shadman, M., Li, H., Rimsza, L., Leonard, J.P., Kaminski, M.S., Braziel, R.M., et al. (2018) Continued Excellent Outcomes in Previously Untreated Patients with Follicular Lymphoma after Treatment with CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of Clinical Oncology, 36, 697-703. [Google Scholar] [CrossRef] 
[10] Maurer, C., Langerbeins, P., Bahlo, J., Cramer, P., Fink, A.M., Pflug, N., et al. (2016) Effect of First-Line Treatment on Second Primary Malignancies and Richter’s Transformation in Patients with CLL. Leukemia, 30, 2019-2025. [Google Scholar] [CrossRef] [PubMed]
[11] Falchi, L, Vitale, C., Keating, M.J., Lerner, S., Wang, X., Elhor Gbito, K.Y., et al. (2016) Incidence and Prognostic Impact of Other Cancers in a Population of Long-Term Survivors of Chronic Lymphocytic Leukemia. Annals of Oncology, 27, 1100-1106. [Google Scholar] [CrossRef] [PubMed]
[12] Bond, D.A., Huang, Y., Fisher, J.L., Ruppert, A.S., Owen, D.H., Bertino, E.M., et al. (2020) Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors. Leukemia, 34, 3197-3205. [Google Scholar] [CrossRef] [PubMed]
[13] Lenartova, A., Johannesen, T.B. and Tjønnfjord, G.E. (2020) Chronic Lymphocytic Leukemia and Secondary Hematological Malignancies: A Nation-Wide Cancer Registry Study. European Journal of Haematology, 104, 546-553. [Google Scholar] [CrossRef] [PubMed]
[14] Ishdorj, G., Beiggi, S., Nugent, Z., Streu, E., Banerji, V., Dhaliwal, D., et al. (2019) Risk Factors for Skin Cancer and Solid Tumors in Newly Diagnosed Patients with Chronic Lymphocytic Leukemia and the Impact of Skin Surveillance on Survival. Leukemia & Lymphoma, 60, 3204-3213. [Google Scholar] [CrossRef] [PubMed]
[15] Mulligan, S.P., Shumack, S. and Guminski, A. (2019) Chronic Lymphocytic Leukemia, Skin and Other Second Cancers. Leukemia & Lymphoma, 60, 3104-3106. [Google Scholar] [CrossRef] [PubMed]
[16] Yang, Y., Yang, Y. and Yan, S. (2021) Risk and Survival of Second Primary Malignancies Following Diagnosis of Gastric Mucosa-Associated Lymphoid Tissue Lymphomas: A Population-Based Study. Current Problems in Cancer, Article ID: 100735. (In Press) [Google Scholar] [CrossRef] [PubMed]
[17] Amiot, A., Jooste,V., Gagniere, C., Lévy, M., Copie-Bergman, C., Dupuis, J. et al. (2017) Second Primary Malignancies in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Leukemia & Lymphoma, 58, 2057-2064. [Google Scholar] [CrossRef] [PubMed]
[18] Tajika, M., Matsuo, K., Ito, H., Chihara, D., Bhatia, V., Kondo, S., et al. (2014) Risk of Second Malignancies in Patients with Gastric Marginal Zone Lymphomas of Mucosa Associate Lymphoid Tissue (MALT). Journal of Gastroenterology, 49, 843-852. [Google Scholar] [CrossRef] [PubMed]
[19] Castillo, J.J., Olszewski, A.J., Hunter, Z.R., Kanan, S., Meid, K. and Treon, S.P. (2015) Incidence of Secondary Malignancies among Patients with Waldenström Macroglobulinemia: An Analysis of the SEER Database. Cancer, 121, 2230-2236. [Google Scholar] [CrossRef] [PubMed]
[20] Wiber, M., Maitre, E., Poncet, J.M., Duchenet, V., Damaj, G., Cornet, E., et al. (2020) A Population-Based Study of Hairy Cell Leukemia over a Period of 20 Years. Cancer Treatment and Research Communications, 25, Article ID: 100236. [Google Scholar] [CrossRef] [PubMed]
[21] Paillassa, J., Cornet, E., Noel, S., Tomowiak, C., Lepretre, S., Vaudaux, S., et al. (2020) Analysis of a Cohort of 279 Patients with Hairy-Cell Leukemia (HCL): 10 Years of Follow-Up. Blood Cancer Journal, 10, Article No. 62. [Google Scholar] [CrossRef] [PubMed]
[22] Pirani, M., Marcheselli, R., Marcheselli, L., Bari, A., Federico, M. and Sacchi, S. (2011) Risk for Second Malignancies in Non-Hodgkin’s Lymphoma Survivors: A Meta-Analysis. Annals of Oncology, 22, 1845-1858. [Google Scholar] [CrossRef] [PubMed]
[23] Luminari, S., Ferrari, A., Manni, M., Dondi, A., Chiarenza, A., Merli, F., et al. (2018) Long-Term Results of the FOLL05 Trial Comparing R-CVP versus R-CHOP versus R-FM for the Initial Treatment of Patients with Advanced-Stage Symptomatic Follicular Lymphoma. Journal of Clinical Oncology, 36, 689-696. [Google Scholar] [CrossRef] 
[24] Flinn, I.W., van der Jagt, R., Kahl, B., Wood, P., Hawkins, T., MacDonald, D., et al. (2019) First-Line Treatment of Patients with Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma with Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. Journal of Clinical Oncology, 37, 984-991. [Google Scholar] [CrossRef] 
[25] Hiddemann, W., Barbui, A.M., Canales, M.A., Cannell, P.K., Collins, G.P., Dürig, J., et al. (2018) Immunochemotherapy with Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology, 36, 2395-2404. [Google Scholar] [CrossRef] 
[26] Olszewski, A.J., Butera, J.N., Reagan, J.L. and Castillo, J.J. (2020) Outcomes of Bendamustine- or Cyclophosphamide-Based First-Line Chemotherapy in Older Patients with Indolent B-Cell Lymphoma. American Journal of Hematology, 95, 354-361. [Google Scholar] [CrossRef] [PubMed]
[27] Federico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., et al. (2013) R-CVP versus R-CHOP versus R-FM for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 31, 1506-1513. [Google Scholar] [CrossRef] 
[28] Colovic, M., Suvajdzic, N., Jankovic, G., Tomin, D., Čolović, N., Denčić Fekete, M., et al. (2011) Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine and Cyclophosphamide. Biomedicine & Pharmacotherapy, 65, 319-321. [Google Scholar] [CrossRef] [PubMed]
[29] Carney, D.A., Westerman, D.A., Tam, C.S., Milner, A., Prince, H.M., Kenealy, M, et al. (2010) Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Following Fludarabine Combination Chemotherapy. Leukemia, 24, 2056-2062. [Google Scholar] [CrossRef] [PubMed]
[30] Epperla, N., Pham, A.Q., Burnette, B.L., Wiseman, G.A., Habermann, T.M., Macon, W.R., et al. (2017) Risk of Histological Transformation and Therapy-Related Myelodysplasia/Acute Myeloid Leukaemia in Patients Receiving Radioimmunotherapy for Follicular Lymphoma. British Journal of Haematology, 178, 427-433. [Google Scholar] [CrossRef] [PubMed]
[31] Byrd, J.C., Hillmen, P.O., O’Brien, S., Barrientos, J.C., Reddy, N.M., Coutre, S., et al. (2019) Long-Term Follow-Up of the RESONATE Phase 3 Trial of Ibrutinib vs Ofatumumab. Blood, 133, 2031-2042. [Google Scholar] [CrossRef] [PubMed]
[32] Coutre, S.E., Byrd, J.C., Hillmen, P., Barrientos, J.C., Barr, P.M., Devereux, S., et al. (2019) Long-Term Safety of Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia in 3 Pivotal Studies. Blood Advanves, 3, 1799-1807. [Google Scholar] [CrossRef] [PubMed]
[33] Treon, S.P., Tripsas, C.K., Meid, K., Warren, D., Varma, G., Green, R., et al. (2015) Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia. New England Journal of Medicine, 372, 1430-1440. [Google Scholar] [CrossRef] 
[34] Tiacci, E., DeCarolis, L., Simonetti, E., Capponi, M., Ambrosetti, A., Lucia, E., et al. (2021) Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. New England Journal of Medicine, 384, 1810-1823. [Google Scholar] [CrossRef] 
[35] Tiacci, E., Park, J.H., DeCarolis, L., Chung, S.S., Broccoli, A., Scott, S., et al. (2015) Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. New England Journal of Medicine, 373, 1733-1747. [Google Scholar] [CrossRef] 

为你推荐